QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
Log in
NASDAQ:ADMS

Adamas Pharmaceuticals Stock Forecast, Price & News

$4.41
-0.12 (-2.65 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.22
Now: $4.41▼
$4.56
50-Day Range
$3.04
MA: $3.95▼
$4.87
52-Week Range
$1.90
Now: $4.41▼
$7.45
Volume119,463 shs
Average Volume420,789 shs
Market Capitalization$125.78 million
P/E RatioN/A
Dividend YieldN/A
Beta2.57
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Adamas Pharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.50 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMS
Previous Symbol
CUSIPN/A
CIK1328143
Webwww.adamaspharma.com
Phone510-450-3500
Employees136

Debt

Debt-to-Equity RatioN/A
Current Ratio3.94
Quick Ratio3.72

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$54.64 million
Price / Sales2.30
Cash FlowN/A
Price / Cash FlowN/A
Book Value($1.21) per share
Price / Book-3.64

Profitability

EPS (Most Recent Fiscal Year)($3.80)
Net Income$-105,190,000.00
Net Margins-89.12%
Return on Equity-806.54%
Return on Assets-43.47%

Miscellaneous

Outstanding Shares28,521,000
Market Cap$125.78 million
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$4.41
-0.12 (-2.65 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

How has Adamas Pharmaceuticals' stock price been impacted by Coronavirus?

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADMS shares have increased by 44.6% and is now trading at $4.41.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Adamas Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Adamas Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Adamas Pharmaceuticals?

Wall Street analysts have given Adamas Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adamas Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Adamas Pharmaceuticals.

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) released its quarterly earnings data on Tuesday, November, 10th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.06. Adamas Pharmaceuticals had a negative net margin of 89.12% and a negative return on equity of 806.54%.
View Adamas Pharmaceuticals' earnings history.

What price target have analysts set for ADMS?

6 brokers have issued 1-year price objectives for Adamas Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they expect Adamas Pharmaceuticals' share price to reach $8.17 in the next twelve months. This suggests a possible upside of 85.2% from the stock's current price.
View analysts' price targets for Adamas Pharmaceuticals.

Are investors shorting Adamas Pharmaceuticals?

Adamas Pharmaceuticals saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 1,200,000 shares, an increase of 60.3% from the October 15th total of 748,500 shares. Based on an average trading volume of 276,900 shares, the short-interest ratio is currently 4.3 days. Currently, 5.2% of the shares of the stock are sold short.
View Adamas Pharmaceuticals' Short Interest.

Who are some of Adamas Pharmaceuticals' key competitors?

Some companies that are related to Adamas Pharmaceuticals include BELLUS Health (BLUSF), CymaBay Therapeutics (CBAY), Avid Bioservices (CDMO), Merus (MRUS), Marinus Pharmaceuticals (MRNS), Inventiva (IVA), AMAG Pharmaceuticals (AMAG), Puma Biotechnology (PBYI), Forte Biosciences (FBRX), Applied Therapeutics (APLT), Humanigen (HGEN), Humanigen (HGEN), Spero Therapeutics (SPRO), Altimmune (ALT) and Viking Therapeutics (VKTX).
View all competitors.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the following people:
  • Mr. Neil F. McFarlane, CEO & Director (Age 47, Pay $784.85k)
  • Mr. Christopher B. Prentiss, Chief Financial Officer (Age 45, Pay $549.47k)
  • Mr. Vijay Shreedhar Ph.D., Chief Commercial Officer (Age 49, Pay $685.89k)
  • Ms. Sarah Mathieson, Head of Corp. Communications, Patient Advocacy & Engagement
  • Mr. Dean Hart, Sr. VP of Sales
  • Dr. Jill M. Jene, Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management (Age 47)
  • Mr. Eric C. Schlezinger, Head of HR (Age 53)
  • Ms. Melissa Masterson, Sr. VP of Commercial Operations & Market Access
  • Mr. Adrian Quartel M.D., Chief Medical Officer

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (2.31%), Assenagon Asset Management S.A. (2.32%), Emerald Advisers LLC (2.27%), BlackRock Inc. (1.88%), Essex Investment Management Co. LLC (1.16%) and Emerald Mutual Fund Advisers Trust (1.09%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went and Jennifer J Rhodes.
View institutional ownership trends for Adamas Pharmaceuticals.

Which institutional investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Bingham Osborn & Scarborough LLC, Jane Street Group LLC, Stonepine Capital Management LLC, Assenagon Asset Management S.A., JPMorgan Chase & Co., BlackRock Inc., and Morgan Stanley.
View insider buying and selling activity for Adamas Pharmaceuticals.

Which institutional investors are buying Adamas Pharmaceuticals stock?

ADMS stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Acadian Asset Management LLC, Squarepoint Ops LLC, Clear Harbor Asset Management LLC, and Connor Clark & Lunn Investment Management Ltd..
View insider buying and selling activity for Adamas Pharmaceuticals.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $4.41.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $125.78 million and generates $54.64 million in revenue each year. The specialty pharmaceutical company earns $-105,190,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis. Adamas Pharmaceuticals employs 136 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.